AstraZeneca maximising innovative portfolio of non insulin anti diabetic medicines - 0 views
-
Alex Parker on 05 Feb 14AstraZeneca has completed the acquisition of Bristol-Myers Squibb's (BMS's) interests in the companies' diabetes alliance for $4.1bn.